Maia Biotechnology Stock Alpha and Beta Analysis
| MAIA Stock | USD 2.41 0.02 0.84% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as MAIA Biotechnology. It also helps investors analyze the systematic and unsystematic risks associated with investing in MAIA Biotechnology over a specified time horizon. Remember, high MAIA Biotechnology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to MAIA Biotechnology's market risk premium analysis include:
Beta 0.29 | Alpha 0.97 | Risk 7.49 | Sharpe Ratio 0.21 | Expected Return 1.56 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out MAIA Biotechnology Analysis, MAIA Biotechnology Valuation, MAIA Biotechnology Correlation, MAIA Biotechnology Hype Analysis, MAIA Biotechnology Volatility, MAIA Biotechnology Price History and analyze MAIA Biotechnology Performance. MAIA Biotechnology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. MAIA Biotechnology market risk premium is the additional return an investor will receive from holding MAIA Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in MAIA Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate MAIA Biotechnology's performance over market.| α | 0.97 | β | 0.29 |
MAIA Biotechnology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of MAIA Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how MAIA Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.MAIA Biotechnology Market Price Analysis
Market price analysis indicators help investors to evaluate how MAIA Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading MAIA Biotechnology shares will generate the highest return on investment. By understating and applying MAIA Biotechnology stock market price indicators, traders can identify MAIA Biotechnology position entry and exit signals to maximize returns.
MAIA Biotechnology Return and Market Media
The median price of MAIA Biotechnology for the period between Tue, Nov 4, 2025 and Mon, Feb 2, 2026 is 1.33 with a coefficient of variation of 33.12. The daily time series for the period is distributed with a sample standard deviation of 0.48, arithmetic mean of 1.46, and mean deviation of 0.35. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romanias 2025 Smart Diaspora Conference on Oncology Research and Innovation | 11/20/2025 |
2 | Acquisition by Vitoc Vlad of 10000 shares of MAIA Biotechnology at 0.9891 subject to Rule 16b-3 | 11/24/2025 |
3 | Acquisition by Smith Stan of 15000 shares of MAIA Biotechnology at 0.98 subject to Rule 16b-3 | 11/25/2025 |
4 | Acquisition by Smith Stan of 4580 shares of MAIA Biotechnology at 1.19 subject to Rule 16b-3 | 12/05/2025 |
5 | MAIA Takes Aim at a 50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach | 12/10/2025 |
6 | MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential | 12/11/2025 |
7 | MAIA Biotechnology Announces 1.51 Million Private Placement | 12/16/2025 |
8 | Swing Trade Why hedge funds are buying MAIA Biotechnology Inc stock - July 2025 Movers Safe Entry Momentum Stock Tips - moha.gov.vn | 12/19/2025 |
9 | Acquisition by Louie Ngar Yee of 81699 shares of MAIA Biotechnology at 1.36 subject to Rule 16b-3 | 12/22/2025 |
10 | MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings | 12/24/2025 |
11 | Acquisition by Chaouki Steven M of 24633 shares of MAIA Biotechnology at 1.53 subject to Rule 16b-3 | 12/31/2025 |
12 | Dr. Munique Maia Announces Harmony Surgery Center, a State-of-the-Art Surgical Center Opening in Tysons Corner in Early 2026 | 01/05/2026 |
13 | MAIA Biotechnology Highlights Strategy in New Investor Presentation - TipRanks | 01/13/2026 |
14 | Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. | 01/20/2026 |
15 | Acquisition by Smith Stan of 24747 shares of MAIA Biotechnology at 1.8 subject to Rule 16b-3 | 01/22/2026 |
16 | Microsoft Unveils A New AI Inference Accelerator Chip, Maia 200 | 01/26/2026 |
17 | Microsoft Maia 200 AI Chip Underscores Long Term Growth Story | 01/28/2026 |
About MAIA Biotechnology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including MAIA or other stocks. Alpha measures the amount that position in MAIA Biotechnology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 1.53 | 2.65 | 3.05 | 3.27 | Net Debt To EBITDA | 0.36 | 0.41 | 0.47 | 0.65 |
MAIA Biotechnology Upcoming Company Events
As portrayed in its financial statements, the presentation of MAIA Biotechnology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MAIA Biotechnology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of MAIA Biotechnology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of MAIA Biotechnology. Please utilize our Beneish M Score to check the likelihood of MAIA Biotechnology's management manipulating its earnings.
| 22nd of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with MAIA Biotechnology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out MAIA Biotechnology Analysis, MAIA Biotechnology Valuation, MAIA Biotechnology Correlation, MAIA Biotechnology Hype Analysis, MAIA Biotechnology Volatility, MAIA Biotechnology Price History and analyze MAIA Biotechnology Performance. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
MAIA Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.